Background Subcutaneous (SC) administration is the preferred parenteral opioid route in palliative care, while intravenous infusion may allow faster titration. Comparative evidence remains limited.

Panelists discuss how the rapid adoption of subcutaneous (SubQ) oncology therapies creates challenges around clinical autonomy, infusion center sustainability, patient experience, and ...

Injection site reactions can occur due to vaccines, Botox, biologics, and chemotherapy. Symptoms often include swelling and itching at the injection site.

Through a focus on safety, innovation and enhanced imaging compatibility, Borvo Medical aims to lead the next generation of subdural hematoma (SDH) treatment solutions.

Borvo EVAC™ System Demonstrates 100% Success Rate in Chronic Subdural Hematoma Clinical Cases Validated Across 5 Medical Centers ...

Department of Neurosurgery, Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, Chiba, Japan Background: Chronic subdural hematoma (cSDH) is one of the most common diseases in ...

Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist has a safety and tolerability profile similar with other GLP-1 and amylin agonists in both oral and subcutaneous formulations, ...

Panelists discuss how integrating subcutaneous (SubQ) therapies into oncology practice involves thorough economic evaluation, coordinated team education, patient engagement, and workflow ...